Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

被引：11
|
作者：
Liu, Ning [1 ]
Yan, Limei [1 ]
Shan, Fengping [2 ]
Wang, Xiaonai [2 ]
Qu, Na [3 ]
Handley, Mike K. [4 ]
Ma, Mingxing [5 ]
机构：
[1] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China
[2] China Med Univ, Dept Immunol, Coll Basic Med Sci, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China
[3] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Gynecol, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning, Peoples R China
[4] Cytocom Inc, 37 North Orange Ave,Suite 607, Orlando, FL 32801 USA
[5] China Med Univ, Shengjing Hosp, Dept Gen Surg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China
来源：
TRANSLATIONAL ONCOLOGY | 2021年 / 14卷 / 04期
关键词：
Low-dose naltrexone; Cervical cancer; Proliferation; Invasion; PI3K; AKT; mTOR; EPITHELIAL-MESENCHYMAL TRANSITION; METASTASIS; SNAIL2; LDN;
D O I：
10.1016/j.tranon.2021.101028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate the expression of OGFr. Additionally, LDN could suppress the abilities of colony formation, migration and invasion in cervical cancer cells. LDN could also inhibit cervical cancer progression in mice model. Moreover, LDN indirectly reduced the expressions of PI3K, pAKT and mTOR in vitro and in vivo. Therefore, LDN may be considered a potential treatment option for cervical cancer.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
    Dobbin, Zachary C.
    Landen, Charles N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (04): : 8213 - 8227
  • [2] The exosome-mediated PI3k/Akt/mTOR signaling pathway in cervical cancer
    Zhang, Wenyuan
    Zhou, Qing
    Wei, Yunhai
    Da, Miao
    Zhang, Chun
    Zhong, Jing
    Liu, Jin
    Shen, Junjun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2019, 12 (07): : 2474 - 2484
  • [3] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [4] α2A-Adrenergic Receptor Inhibits the Progression of Cervical Cancer Through Blocking PI3K/AKT/mTOR Pathway
    Wang, Weina
    Guo, Xin
    Dan, Huiwen
    ONCOTARGETS AND THERAPY, 2020, 13 : 10535 - 10546
  • [5] CENPF facilitates endometrial cancer cell progression through PI3K/AKT/mTOR pathway
    Xiao, Huan
    Zhang, Zhi'an
    Wei, Chunqing
    Peng, Dan
    Guo, Yuge
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2023, 44 (01) : 106 - 114
  • [6] Pterostilbene inhibits gallbladder cancer progression by suppressing the PI3K/Akt pathway
    Tong, Chenhao
    Wang, Yali
    Li, Jiandong
    Cen, Wenda
    Zhang, Weiguang
    Zhu, Zhiyang
    Yu, Jianhua
    Lu, Baochun
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [7] Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway
    Bai, Xue
    Ma, Yaxin
    Zhang, Guobin
    ONCOLOGY REPORTS, 2015, 33 (06) : 3085 - 3092
  • [8] Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer
    Akbarzadeh, Maryam
    Mihanfar, Ainaz
    Akbarzadeh, Shabnam
    Yousefi, Bahman
    Majidinia, Maryam
    LIFE SCIENCES, 2021, 285
  • [9] Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
    Li, Huayi
    Prever, Lorenzo
    Hirsch, Emilio
    Gulluni, Federico
    CANCERS, 2021, 13 (14)
  • [10] PI3K/Akt/mTOR signaling pathway in cancer stem cells
    Fath, Mohsen Karami
    Ebrahimi, Menooa
    Nourbakhsh, Ehsan
    Hazara, Ahmad Zia
    Mirzaei, Ali
    Shafieyari, Saba
    Salehi, Azadeh
    Hoseinzadeh, Mahsa
    Payandeh, Zahra
    Barati, Ghasem
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 237
12345